Suppr超能文献

免疫介导性坏死性肌病(IMNM):抗体的故事

Immune-Mediated Necrotizing Myopathy (IMNM): A Story of Antibodies.

作者信息

Julien Sarah, Challier Inès, Malleter Marine, Jouen Fabienne, Drouot Laurent, Boyer Olivier

机构信息

INSERM U1234, PAn'THER FOCIS Center of Excellence, Université de Rouen, F-76000 Rouen, France.

Department of Pharmacy, CHU Rouen, F-76000 Rouen, France.

出版信息

Antibodies (Basel). 2024 Feb 7;13(1):12. doi: 10.3390/antib13010012.

Abstract

Immune-mediated necrotizing myopathy (IMNM) is a rare and severe disease that corresponds to a specific entity of idiopathic inflammatory myopathy. Patients with IMNM suffer from proximal muscle weakness, and present high levels of creatine kinase and necrotic myofibers. Anti-Signal Recognition Particle (SRP) and anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies (HMGCR) have recently been identified in two thirds of patients with IMNM and are used as a hallmark of the disease. In this review, we provide a detailed description of these antibodies and the tests used to detect them in the serum of patients. Based on in vitro studies and mouse models of IMNM, we discuss the role of autoantibodies in the pathogenesis of the disease. Finally, in the light of the latest knowledge, we conclude with a review of recent therapeutic approaches in IMNM.

摘要

免疫介导性坏死性肌病(IMNM)是一种罕见且严重的疾病,属于特发性炎性肌病的一个特定类型。IMNM患者存在近端肌无力,肌酸激酶水平升高且有坏死性肌纤维。近期在三分之二的IMNM患者中发现了抗信号识别颗粒(SRP)和抗3-羟基-3-甲基戊二酰辅酶A还原酶自身抗体(HMGCR),它们被用作该疾病的标志。在本综述中,我们详细描述了这些抗体以及用于检测患者血清中这些抗体的检测方法。基于IMNM的体外研究和小鼠模型,我们讨论了自身抗体在该疾病发病机制中的作用。最后,根据最新知识,我们对IMNM最近的治疗方法进行了综述。

相似文献

2
Immune-Mediated Necrotizing Myopathy.免疫介导性坏死性肌病。
Curr Rheumatol Rep. 2018 Mar 26;20(4):21. doi: 10.1007/s11926-018-0732-6.
3
[Clinical and pathological characteristics of immune mediated necrotizing myopathy].免疫介导性坏死性肌病的临床与病理特征
Beijing Da Xue Xue Bao Yi Xue Ban. 2019 Dec 18;51(6):989-995. doi: 10.19723/j.issn.1671-167X.2019.06.002.
6
Pediatric immune-mediated necrotizing myopathy.儿童免疫介导性坏死性肌病
Front Neurol. 2023 Mar 20;14:1123380. doi: 10.3389/fneur.2023.1123380. eCollection 2023.

本文引用的文献

1
Refractory dermatomyositis responsive to anifrolumab.对阿尼鲁单抗有反应的难治性皮肌炎
JAAD Case Rep. 2023 Nov 7;43:27-29. doi: 10.1016/j.jdcr.2023.10.023. eCollection 2024 Jan.
2
FDA Investigating CAR-Related T-cell Malignancies.FDA 正在调查与 CAR-T 细胞相关的 T 细胞恶性肿瘤。
Cancer Discov. 2024 Jan 12;14(1):9-10. doi: 10.1158/2159-8290.CD-NB2023-0091.
6
Belimumab treatment of adult idiopathic inflammatory myopathy.贝利尤单抗治疗成人特发性炎性肌病。
Rheumatology (Oxford). 2024 Mar 1;63(3):742-750. doi: 10.1093/rheumatology/kead281.
9
CD19-targeted CAR T cells in refractory antisynthetase syndrome.难治性抗合成酶综合征中靶向CD19的嵌合抗原受体T细胞
Lancet. 2023 Mar 11;401(10379):815-818. doi: 10.1016/S0140-6736(23)00023-5. Epub 2023 Feb 15.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验